Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

Kathleen C. Suozzi, Maximilian Stahl, Christine J. Ko, Anne C. Chiang, Scott Gettinger, Mark D. Siegel, Christopher G. Bunick

JAAD Case Reports · 2016 · 100 citations · 10 references

DOIFull text

Open access

Concepts

Abstract

Immune checkpoint inhibitors show remarkable antitumor activity across multiple tumor types, with approval of programmed death–1 (PD-1) inhibitors for non–small cell lung cancer and melanoma. A recent clinical trial found median progression-free survival of 11.5 months for combined nivolumab plus ipilimumab therapy for metastatic melanoma compared with 6.9 months (nivolumab alone) or 2.9 months (ipilimumab alone).1 Nivolumab, a fully human IgG4 PD-1 antagonist antibody, and ipilimumab, a fully human IgG1 cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antagonist antibody, act by relieving suppression of antitumor T cells.

References

10